The Amgen and Celgene-backed pharmaceutical company raised the cash after pulling in $72m in venture funding over two years.
US-based biopharmaceutical company Atara Biosciences raised $55m from an initial public offering last week, issuing 5 million shares priced at $11.00 each.
Spun out from pharmaceutical firm Amgen in 2012, Atara raised $72m across two rounds from investors including Amgen’s corporate venturing subsidiary, Amgen Ventures, and another pharmaceutical company, Celgene.
Amgen’s stake was diluted from 8.6% to 7.7% through the offering, while Celgene retains a 6.5% share.
Other notable shareholders post-IPO are Kleiner Perkins Caufield & Byers (13.8%), Baupost Group…
